148 related articles for article (PubMed ID: 12593442)
41. Epstein-Barr virus infection in precursor lesions of nasopharyngeal carcinoma.
Zhong BL; Zong YS; Lin SX; Zhang M; Liang YJ
Ai Zheng; 2006 Feb; 25(2):136-42. PubMed ID: 16480574
[TBL] [Abstract][Full Text] [Related]
42. [Significance of detection of serum sialic acid and Epstein-Barr virus VCA-IgA in diagnosis and monitoring radiotherapy effectiveness in nasopharyngeal carcinoma patients].
Jiang LN; Dai LC; He JF; Chen YW; Ma ZH
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):30-2. PubMed ID: 16816858
[TBL] [Abstract][Full Text] [Related]
43. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
[TBL] [Abstract][Full Text] [Related]
44. Hypermethylation of epithelial-cadherin gene promoter is associated with Epstein-Barr virus in nasopharyngeal carcinoma.
Niemhom S; Kitazawa S; Kitazawa R; Maeda S; Leopairat J
Cancer Detect Prev; 2008; 32(2):127-34. PubMed ID: 18632221
[TBL] [Abstract][Full Text] [Related]
45. Detection and analysis of anti-latent membrane protein 2A antibodies in the sera of patients with Epstein-Barr virus associated malignancies.
Chen Y; Yao K; Sun H; Qing J; Peng GY
Chin Med J (Engl); 2005 May; 118(9):725-30. PubMed ID: 15899133
[TBL] [Abstract][Full Text] [Related]
46. Serum Epstein-Barr virus DNA load in primary Epstein-Barr virus infection.
Bauer CC; Aberle SW; Popow-Kraupp T; Kapitan M; Hofmann H; Puchhammer-Stöckl E
J Med Virol; 2005 Jan; 75(1):54-8. PubMed ID: 15543583
[TBL] [Abstract][Full Text] [Related]
47. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups.
Henle W; Henle G; Ho HC; Burtin P; Cachin Y; Clifford P; de Schryver A; de-Thé G; Diehl V; Klein G
J Natl Cancer Inst; 1970 Jan; 44(1):225-31. PubMed ID: 11515035
[No Abstract] [Full Text] [Related]
48. Evaluation of plasma Epstein-Barr virus DNA load as a prognostic marker for nasopharyngeal carcinoma.
Tan EL; Looi LM; Sam CK
Singapore Med J; 2006 Sep; 47(9):803-7. PubMed ID: 16924363
[TBL] [Abstract][Full Text] [Related]
49. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.
Shao JY; Zhang Y; Li YH; Gao HY; Feng HX; Wu QL; Cui NJ; Cheng G; Hu B; Hu LF; Ernberg I; Zeng YX
Anticancer Res; 2004; 24(6):4059-66. PubMed ID: 15736452
[TBL] [Abstract][Full Text] [Related]
50. Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion.
Ho CH; Chen CL; Li WY; Chen CJ
Carcinogenesis; 2009 Aug; 30(8):1443-51. PubMed ID: 19483191
[TBL] [Abstract][Full Text] [Related]
51. Cytomegalovirus isolations from cell cultures derived from Epstein-Barr virus-associated nasopharyngeal carcinoma.
Desgranges C; Seigneurin JM; Baccard M; Nejmi S
J Natl Cancer Inst; 1983 Jul; 71(1):39-43. PubMed ID: 6306325
[TBL] [Abstract][Full Text] [Related]
52. [The usefulness of serum antibody to Epstein-Barr virus-specific DNAase (EDAb) in early detection of nasopharyngeal carcinoma].
Huang D
Zhonghua Zhong Liu Za Zhi; 1993 Jul; 15(4):289-91. PubMed ID: 8174467
[TBL] [Abstract][Full Text] [Related]
53. [Real-time quantitative PCR assay of Epstein-Barr virus in whole blood cells of nasopharyngeal carcinoma patients].
Wang H; Deng L; Chen SH; Wang SQ; Cao Y
Shi Yan Sheng Wu Xue Bao; 2003 Feb; 36(1):32-6. PubMed ID: 12751207
[TBL] [Abstract][Full Text] [Related]
54. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA.
Hong RL; Lin CY; Ting LL; Ko JY; Hsu MM
Cancer; 2004 Apr; 100(7):1429-37. PubMed ID: 15042677
[TBL] [Abstract][Full Text] [Related]
55. Epstein-Barr virus (EBV) serology for predicting distant metastases in a white juvenile patient with nasopharyngeal carcinoma and no clinical response to EBV lytic induction therapy.
Stevens SJ; Zwaan CM; Verkuijlen SA; Middeldorp JM
Head Neck; 2006 Nov; 28(11):1040-5. PubMed ID: 16933315
[TBL] [Abstract][Full Text] [Related]
56. [Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].
Li YH; Shao JY; Zhao MQ; Gao HY; Li LR; Guan ZZ; Zeng YX
Ai Zheng; 2003 Jun; 22(6):645-8. PubMed ID: 12948418
[TBL] [Abstract][Full Text] [Related]
57. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis.
Pohl D; Krone B; Rostasy K; Kahler E; Brunner E; Lehnert M; Wagner HJ; Gärtner J; Hanefeld F
Neurology; 2006 Dec; 67(11):2063-5. PubMed ID: 17159123
[TBL] [Abstract][Full Text] [Related]
58. [Nasopharyngeal carcinoma: present and future].
Ooka T
Nihon Rinsho; 1997 Feb; 55(2):334-45. PubMed ID: 9046820
[TBL] [Abstract][Full Text] [Related]
59. [Improve on serological diagnosis method of nasopharyngeal carcinoma].
Zhan SB; Zhong JM; Mai ZP; Ye SQ; Zhou L; Zeng Y; Liao J
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Feb; 23(1):65-7. PubMed ID: 19799023
[TBL] [Abstract][Full Text] [Related]
60. [Detection of EBV by PCR in fresh and paraffin embedded samples of cavum tumour].
Charef S; Jrad BB; Mahfouth W; Zakhama A; Kassab A; Driss N; Chouchane L
Arch Inst Pasteur Tunis; 2006; 83(1-4):41-7. PubMed ID: 19388596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
